Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Richard Congo"'
Autor:
Casey Pence, Majed Matar, David Ulkoski, Leslie Wilkinson, Jason G. Fewell, Elaine Brunhoeber, Kirby Wallace, Diane McClure, Gregory Slobodkin, Jennifer Rice, Richard Congo, Angela Rea-Ramsey, Kevin Polach, Jeff Sparks, Khursheed Anwer
Publikováno v:
Journal of Controlled Release. 158:269-276
Exploitation of the RNA interference (RNAi) pathway offers the promise of new and effective therapies for a wide variety of diseases. Clinical development of new drugs based on this platform technology is still limited, however, by a lack of safe and
Autor:
Anke Geick, Kerstin Jahn-Hofmann, Monika Krampert, Jennifer Rice, Andrea Schuster, Khursheed Anwer, Richard Congo, Hans-Peter Vornlocher, Gregory Slobodkin, Jason G. Fewell, Diane McClure, Matthias John, Jeff Sparks, Angela Rea-Ramsey, Kevin Polach, Majed Matar, Elaine Brunhoeber
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 20(1)
We have designed a series of versatile lipopolyamines which are amenable to chemical modification for in vivo delivery of small interfering RNA (siRNA). This report focuses on one such lipopolyamine (Staramine), its functionalized derivatives and the
Autor:
Elaine Brunhoeber, Richard Congo, Gregory Slobodkin, Jennifer Rice, Angela Rea-Ramsey, Khursheed Anwer, Jason G. Fewell, Jeff Sparks, Kevin Polach, Casey Pence, Majed Matar, Diane McClure, Leslie Wilkinson
Publikováno v:
Cancer Research. 71:4995-4995
RNA interference offers the promise of a new class of therapeutics that can specifically target many diseases that have aberrant gene expression as the root cause. This is potentially true even for diseases that are currently considered non-druggable
Autor:
Jason G. Fewell, Diane McClure, Jeff Sparks, Majed Matar, Angela Rea-Ramsey, Elaine Brunhoeber, Jennifer Rice, Gregory Slobodkin, Richard Congo, Khursheed Anwer, Casey Pence, Kevin Polach, Leslie Wilkinson
Publikováno v:
Cancer Research. 70:5535-5535
The efficient delivery of siRNA molecules to target cells is critical for the application of RNAi to the treatment of human cancers. To this end, we have developed novel cationic lipopolyamime structures that can be used to complex or encapsulate siR